Fig. 5: IDA/XPA also combats enzalutamide resistance in prostate cancer cells.
A–C LNCaP/ENZ cells were injected subcutaneously into the flanks of 8-week-old castrated male null mice. When tumor sizes reached ~50 mm3, mice were administered with the vehicle (10% DMSO plus 90% corn oil mixture as control, n = 10), IDA (0.25 mg/kg, i.p.), EZN (10 mg/kg, i.g.), and combination EZN (10 mg/kg) and IDA (0.25 mg/kg) (A). Tumor volume (B) and survival (n = 10, per group) (C) were monitored as indicated days. D, E LNCaP/ENZ (D) and 22RV1/ENZ(E) cells were treated with DMSO, IDA(0.25 μM), ENZ(10 μM), and a combination of ENZ with IDA for 24 h. XPA protein levels, γH2AX, and AR were determined by western blot. F. LNCaP/ENZ and 22RV1/ENZ cells were treated with DMSO, MG132(1 μM), and CQ(30 μM) with or without IDA(0.25 μM) for 24 h. XPA protein levels were determined by western blot. Data are presented as means ± s.e.m. Statistical analysis for tumor growth and overall animal survival were performed using two-way ANOVA analysis (B) and Log-rank (Mantel–Cox) test analysis (C), respectively. The asterisks indicate significant differences between the indicated groups (*p < 0.05, ***p < 0.001).
